Endocrine Testing Market - By Test Type (Human Chorionic Gonadotropin (hCG) Hormone Test, Insulin Test), By Technology (Mass Spectroscopy, Immunoassay), By End-use (Hospitals, Clinical Laboratories) & Forecast, 2023

List of Tables

Global Endocrine Testing Market will register significant growth between 2023 and 2032.

The consistent rise in the geriatric population worldwide will drive industry growth over the next ten years. According to WHO, people aged over 60 years will account for 22% of the world's population by 2050. Aging people have a greater susceptibility to endocrine disorders, such as diabetes, thyroid dysfunction, and adrenal gland disorders, that require accurate diagnostic tests, thereby contributing to market expansion. Technological advancements in diagnostic techniques and the introduction of innovative endocrine testing products are also playing a crucial role in fueling market growth. Moreover, the growing awareness among individuals regarding preventive healthcare and early disease detection is propelling the adoption of endocrine testing, driving market revenues.

The overall endocrine testing market share is categorized based on test, technology, end-use, and region.

Regarding the test, the insulin segment is poised to capture a decent market share by 2032. The demand for insulin tests is primarily driven by the escalating prevalence of diabetes worldwide. According to CDC 2022 National Diabetes Statistics Report, an estimated 130 million adults in the US are living with diabetes or prediabetes. As diabetes cases continue to rise, the need to accurately measure insulin levels becomes essential for effective disease management and personalized treatment plans. Insulin tests play a critical role in diagnosing diabetes, monitoring treatment efficacy, and preventing complications, contributing to the sustained demand for such tests.

In terms of technology, the endocrine testing industry size from the chromatography segment will expand at a notable CAGR through 2032. Chromatography testing is highly sensitive and accurate and can analyze multiple hormones simultaneously. This technique offers efficient separation and detection of complex hormone mixtures, aiding in precise diagnosis and monitoring of endocrine disorders. The growing demand for reliable and comprehensive diagnostic methods is propelling the adoption of chromatography-based testing in the field of endocrinology.

Diagnostic centers are anticipated to emerge as a prominent end-user for endocrine testing by 2032. The increasing prevalence of endocrine disorders, coupled with the aging population, drives the need for accurate and timely hormone assessments. Moreover, advancements in testing technologies have made endocrine assays more accessible, leading to higher adoption in diagnostic centers, enabling early detection and effective management of endocrine-related conditions.

Europe endocrine testing industry will record significant revenue through 2032. The region's aging population contributes to a higher prevalence of endocrine disorders, increasing the need for comprehensive testing. Additionally, rising awareness about preventive healthcare and early disease detection fuels the demand for endocrine tests, aiding in timely intervention and treatment. Advances in diagnostic technologies also make endocrine testing more accessible, further driving its popularity in Europe.

Product Code: 5653

Chapter 1 Methodology & Scope

1.1 Industry coverage
1.2 Market scope & definition
1.3 Base estimates & calculations
- 1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact analysis at global level
1.6 Data validation
1.7 Data Sources
- 1.7.1 Primary
- 1.7.2 Secondary
  - 1.7.2.1 Paid sources
  - 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Endocrine testing industry 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Regional trends
2.4 Test type trends
2.5 Technology trends
2.6 End-use trends

Chapter 3 Endocrine Testing Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of diabetes, thyroid, and obesity
  - 3.2.1.2 Rising prevalence of endocrine disorders
  - 3.2.1.3 Supportive government funding initiatives
  - 3.2.1.4 Technological developments
  - 3.2.1.5 Growing awareness of routine health monitoring
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost for the development of testing technologies
  - 3.2.2.2 Lack of awareness in underdeveloped & developing countries
3.3 Growth potential analysis
- 3.3.1 By test type
- 3.3.2 By technology
- 3.3.3 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Reimbursement scenario
3.7 Key market trends
3.8 Technological advancements
3.9 Application potential
3.10 Initiatives landscape
3.11 GAP analysis
3.12 Porter's analysis
3.13 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Global company market share analysis, 2022
4.4 Vendor matrix anaylsis
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Endocrine Testing Market Size and Forecast, By Test Type (USD Million & Units)

5.1 Key trends, by test type
5.2 Human Chorionic Gonadotropin (hCG) Hormone Test
5.3 Luteinizing Hormone (LH) Test
5.4 Progesterone Test
5.5 Thyroid Stimulating Hormone (TSH) Test
5.6 Prolactin Test
5.7 Insulin Test
5.8 Others

Chapter 6 Endocrine Testing Market Size and Forecast, By Technology (USD Million)

6.1 Key trends, by technology
6.2 Mass Spectroscopy
6.3 Immunoassay
6.4 Chromatography
6.5 Nucleic Acid Based
6.6 Others

Chapter 7 Endocrine Testing Market Size and Forecast, By End-use (USD Million)

7.1 Key trends, by end-use
7.2 Hospitals
7.3 Clinical Laboratories
7.4 Diagnostic Centers
7.5 Others

Chapter 8 Endocrine Testing Market Size and Forecast, By Region (USD Million & Units)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Poland
- 8.3.7 Switzerland
- 8.3.8 The Netherlands
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Indonesia
- 8.4.7 Philippines
- 8.4.8 Vietnam
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.5.4 Colombia
- 8.5.5 Chile
- 8.5.6 Peru
8.6 MEA
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Israel
- 8.6.5 Egypt
- 8.6.6 Turkey

Chapter 9 Company Profiles

9.1 Bio-Rad Laboratories, Inc.
9.2 Agilent Technologies, Inc.
9.3 bioMerieux SA
9.4 F. Hoffmann-La Roche Ltd
9.5 Siemens Healthineers
9.6 Abbott Laboratories, Inc.
9.7 DiaSorin S.p.A
9.8 Beckman Coulter, Inc.
9.9 AB Sciex
9.10 Laboratory Corporation of America Holdings
9.11 Quest Diagnostics Incorporated
9.12 Thermo Fischer Scientific
9.13 DH Tech. Dev. Pte. Ltd.
9.14 Biomedical Technologies Limited
9.15 Ortho Clinical Diagnostics
9.16 QIAGEN N.V.